NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 2nd August 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Dr Bushra Hasnie Present for all items
4. Dr Francis Drobniewski Present for all items
5. Dr Daniel Gallacher Present for all items
6. Dr Veline L’Esperance Present for all items
7. Dr Andrew Makin Present for all items
8. Dr Rhiannon Owen Present for all items
9. Mariana Bacelar Present for all items
10. Anna Pracz Present for all items
11. Gabriel Rogers  Present for all items
12. Nigel Westwood Present for all items
13. Peter Wheatley-Price Present for all items
14. Tony Wootton Present for all items
15. Malcolm Oswald Items 5.1 to 6.3.2
16. Carole Pitkeathley Present for all items
17. Stella O’Brien Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director Present for all items

Richard Diaz, Associate Director Present for all items

Leena Issa, Project Manager Items 1.1 to 5.3.2

Alexandra Filby, Health Technology Assessment Adviser Items 1.1 to 4.3.2

George Millington, Heath Technology Assessment Analyst Items 1.1 to 4.3.2

Lizzie Walker, Heath Technology Assessment Adviser Items 5.1 to 5.3.2

Anna Willis, Heath Technology Assessment Analyst Items 5.1 to 5.3.2

Wajeeha Asim, Administrator, Technology Appraisals Items 1.1 to 5.3.2

Carl Jackson, Assistant Project Manager, COT Items 1.1 to 4.2.2

Portia Dodds, Coordinator, COT Present for all items

External assessment group representatives present

Claire Rothery, York Items 1.1 to 4.1.3

Mark Corbett, York Items 1.1 to 4.1.3

Mekazin Tsehaye, Aberdeen HTA Group Items 5.1 to 5.1.3

Dwayne Boyers, Aberdeen HTA Group Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

[Ser-ling Chua](http://niceplan2/Appraisals_TestLive/Experts17.aspx?ACID=4054) , Consultant dermatologist, Clinical Expert nominated by British Association of Dermatologists Items 1.1 to 4.1.3

[Rachel Hardwick](http://niceplan2/Appraisals_TestLive/Experts17.aspx?ACID=4054)  Prurigo Nodularis International Patient Lead, Patient expert nominated by Nodular Prurigo International (support group) Items 1.1 to 4.1.3

Sailaja Maganti, Prurigo Nodularis International Patient Lead, Patient expert nominated by Nodular Prurigo International (support group) Items 1.1 to 4.1.3

John Ingram, Clinical Reader & Consultant Dermatologist, Clinical Expert nominated by Novartis Pharmaceutical UK Limited Items 5.1 to 5.1.3

Ruth Lamb, Consultant Dermatologist, Clinical Expert nominated by British Association of Dermatologists Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Charles Crawley welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Professor David McAllister, Professor Iolo Doull, Dr Stuart Williams, Dr Toby Smith, Dr Warren Linley, Mariana Bacelar, Dr Alistair Patton, and Dr Hatim Abdulhussien.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 6 July 2023.
1. **Appraisal of** **Dupilumab for treating prurigo nodularis [ID4054]**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Sanofi.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11081).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Nigel Westwood (Lay), Dr Francis Drobniewski (Clinical) and Mariana Bacelar (Cost).
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached .
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11081>
1. **Appraisal of** [**Secukinumab for treating moderate to severe hidradenitis suppurativa [ID4039]**](https://www.nice.org.uk/guidance/indevelopment/gid-ta11095)
	1. Part 1 – Open session
		1. The Vice Chair, Baljit Singh, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11095).
		3. The Vice Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Baljit Singh.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11095>.

[**Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]**](https://www.nice.org.uk/guidance/indevelopment/gid-ta10730)

* The discussion of this appraisal was postponed and will be rescheduled to a future meeting date.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 6 September 2023 and will start promptly at 9am.